The Ensign Group, Inc.
ENSG Healthcare Medical Care Facilities
The Ensign Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 18.7% from fiscal 2024. In the quarter to June 2026, revenue grew 17.3%, EPS grew 16.2%, free cash flow grew 12.2% and total debt fell 2.77%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for five.
Follow ENSG
The Ensign Group, Inc. (ENSG) EV/Sales
As of 16 October 2026, The Ensign Group, Inc. (ENSG) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 0.6× (November 2016) to 2.4× (March 2026); the current reading is higher than 84% of that period. That is above the Medical Care Facilities industry median of 1.3× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | 12.60% |
| FY2024 | 1.7× | 4.09% |
| FY2023 | 1.6× | (2.66%) |
| FY2022 | 1.7× | (2.37%) |
| FY2021 | 1.7× | 8.30% |
| FY2020 | 1.6× | 19.15% |
| FY2019 | 1.3× | 10.26% |
| FY2018 | 1.2× | 39.21% |
| FY2017 | 0.9× | 11.30% |
| FY2016 | 0.8× | (7.95%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.7× | (21.72%) |
| Mar 2026 | 2.1× | 12.31% |
| Dec 2025 | 1.9× | (4.50%) |
| Sep 2025 | 2.0× | 6.83% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FMS Fresenius Medical Care AG & Co. KGaA compare | 0.8× |
| UHS Universal Health Services, Inc. compare | 0.9× |
| PACS PACS Group, Inc. compare | 1.4× |
| THC Tenet Healthcare Corporation compare | 1.5× |
| DVA DaVita Inc. compare | 1.6× |
| ENSG The Ensign Group, Inc. | 1.8× |
| EHC Encompass Health Corporation compare | 2.4× |
| CHE Chemed Corporation compare | 2.6× |
| CON Concentra Group Holdings Parent, Inc. compare | 2.7× |
| Medical Care Facilities industry median | 1.3× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)